on Biophytis (EPA:ALBPS)
Biophytis extends its contract with Atlas to finance its clinical activities
Biophytis SA, a biotechnology company specializing in the treatment of age-related diseases, announces the extension of its financing agreement with the Atlas investment fund. This amendment allows the issuance of convertible bonds of up to 16 million euros by June 2026.
This funding aims to support the development of the OBA clinical programs for obesity and MYODA in Duchenne Muscular Dystrophy. Biophytis has received authorizations for these programs, and the first studies are expected to begin in mid-2024.
The contract could extend Biophytis' cash horizon until the end of 2024. However, the financing carries risks of dilution for current shareholders and volatility for the stock price. Investors are urged to be vigilant.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news